^Bonaccorsi L; Carloni Vinicio; Muratori Monica; Formigli Lucia; Zecchi Sandra; Forti Gianni; Baldi Elisabetta (2004). „EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR)”. Int. J. Cancer. 112 (1): 78—86. PMID15305378. doi:10.1002/ijc.20362.
^Bonaccorsi L, Muratori M, Carloni V, Marchiani S, Formigli L, Forti G, Baldi E (2004). „The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells”. Steroids. 69 (8-9): 549—52. PMID15288768. doi:10.1016/j.steroids.2004.05.011.
^Kim S-W; Hayashi Masaaki; Lo Jeng-Fan; Yang Young; Yoo Jin-San; Lee Jiing-Dwan (2003). „ADP-ribosylation factor 4 small GTPase mediates epidermal growth factor receptor-dependent phospholipase D2 activation”. J. Biol. Chem. 278 (4): 2661—8. PMID12446727. doi:10.1074/jbc.M205819200.
^ абCouet J, Sargiacomo M, Lisanti MP (1997). „Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities”. J. Biol. Chem. 272 (48): 30429—38. PMID9374534. doi:10.1074/jbc.272.48.30429.
^ абTvorogov D; Carpenter Graham (2002). „EGF-dependent association of phospholipase C-gamma1 with c-Cbl”. Exp. Cell Res. 277 (1): 86—94. PMID12061819. doi:10.1006/excr.2002.5545.
^ абEttenberg SA, Keane MM, Nau MM, Frankel M, Wang LM, Pierce JH, Lipkowitz S (1999). „cbl-b inhibits epidermal growth factor receptor signaling”. Oncogene. 18 (10): 1855—66. PMID10086340. doi:10.1038/sj.onc.1202499.
^Kim M, Tezuka T, Suziki Y, Sugano S, Hirai M, Yamamoto T (1999). „Molecular cloning and characterization of a novel cbl-family gene, cbl-c”. Gene. 239 (1): 145—54. PMID10571044. doi:10.1016/S0378-1119(99)00356-X.
^Keane MM, Ettenberg SA, Nau MM, Banerjee P, Cuello M, Penninger J, Lipkowitz S (1999). „cbl-3: a new mammalian cbl family protein”. Oncogene. 18 (22): 3365—75. PMID10362357. doi:10.1038/sj.onc.1202753.
^Wang Z, Wang M, Lazo JS, Carr BI (2002). „Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase”. J. Biol. Chem. 277 (22): 19470—5. PMID11912208. doi:10.1074/jbc.M201097200.
^Hashimoto Y, Katayama H, Kiyokawa E, Ota S, Kurata T, Gotoh N, Otsuka N, Shibata M, Matsuda M (1998). „Phosphorylation of CrkII adaptor protein at tyrosine 221 by epidermal growth factor receptor”. J. Biol. Chem. 273 (27): 17186—91. PMID9642287. doi:10.1074/jbc.273.27.17186.
^Hazan RB, Norton L (1998). „The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton”. J. Biol. Chem. 273 (15): 9078—84. PMID9535896. doi:10.1074/jbc.273.15.9078.
^Schroeder JA; Adriance Melissa C; McConnell Elizabeth J; Thompson Melissa C; Pockaj Barbara; Gendler Sandra J (2002). „ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas”. J. Biol. Chem. 277 (25): 22692—8. PMID11950845. doi:10.1074/jbc.M201975200.
^Takahashi K, Suzuki K, Tsukatani Y (1997). „Induction of tyrosine phosphorylation and association of beta-catenin with EGF receptor upon tryptic digestion of quiescent cells at confluence”. Oncogene. 15 (1): 71—8. PMID9233779. doi:10.1038/sj.onc.1201160.
^Santra M, Reed Charles C, Iozzo Renato V (2002). „Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping but distinct from the EGF-binding epitope”. J. Biol. Chem. 277 (38): 35671—81. PMID12105206. doi:10.1074/jbc.M205317200.
^Iozzo RV, Moscatello DK, McQuillan DJ, Eichstetter I (1999). „Decorin is a biological ligand for the epidermal growth factor receptor”. J. Biol. Chem. 274 (8): 4489—92. PMID9988678. doi:10.1074/jbc.274.8.4489.
^ абWong L, Deb TB, Thompson SA, Wells A, Johnson GR (1999). „A differential requirement for the COOH-terminal region of the epidermal growth factor (EGF) receptor in amphiregulin and EGF mitogenic signaling”. J. Biol. Chem. 274 (13): 8900—9. PMID10085134. doi:10.1074/jbc.274.13.8900.
^Stortelers C; Souriau Christelle; van Liempt Ellis; van de Poll Monique L M; van Zoelen Everardus J J (2002). „Role of the N-terminus of epidermal growth factor in ErbB-2/ErbB-3 binding studied by phage display”. Biochemistry. 41 (27): 8732—41. PMID12093292. doi:10.1021/bi025878c.
^ абDaly RJ, Sanderson GM, Janes PW, Sutherland RL (1996). „Cloning and characterization of GRB14, a novel member of the GRB7 gene family”. J. Biol. Chem. 271 (21): 12502—10. PMID8647858. doi:10.1074/jbc.271.21.12502.
^ абвBraverman LE, Quilliam LA (1999). „Identification of Grb4/Nckbeta, a src homology 2 and 3 domain-containing adapter protein having similar binding and biological properties to Nck”. J. Biol. Chem. 274 (9): 5542—9. PMID10026169. doi:10.1074/jbc.274.9.5542.
^Oneyama C; Nakano Hirofumi; Sharma Sreenath V (2002). „UCS15A, a novel small molecule, SH3 domain-mediated protein-protein interaction blocking drug”. Oncogene. 21 (13): 2037—50. PMID11960376. doi:10.1038/sj.onc.1205271.
^Okutani T, Okabayashi Y, Kido Y, Sugimoto Y, Sakaguchi K, Matuoka K, Takenawa T, Kasuga M (1994). „Grb2/Ash binds directly to tyrosines 1068 and 1086 and indirectly to tyrosine 1148 of activated human epidermal growth factor receptors in intact cells”. J. Biol. Chem. 269 (49): 31310—4. PMID7527043.
^Tortora G, Damiano V, Bianco C, Baldassarre G, Bianco AR, Lanfrancone L, Pelicci PG, Ciardiello F (1997). „The RIalpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor”. Oncogene. 14 (8): 923—8. PMID9050991. doi:10.1038/sj.onc.1200906.
^ абBuday L, Egan SE, Rodriguez VP, Cantrell DA, Downward J (1994). „A complex of Grb2 adaptor protein, Sos exchange factor, and a 36-kDa membrane-bound tyrosine phosphoprotein is implicated in ras activation in T cells”. J. Biol. Chem. 269 (12): 9019—23. PMID7510700.
^Lowenstein EJ, Daly RJ, Batzer AG, Li W, Margolis B, Lammers R, Ullrich A, Skolnik EY, Bar-Sagi D, Schlessinger J (1992). „The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling”. Cell. 70 (3): 431—42. PMID1322798. doi:10.1016/0092-8674(92)90167-B.
^ абвгдOlayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE (1999). „ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases”. J. Biol. Chem. 274 (24): 17209—18. PMID10358079. doi:10.1074/jbc.274.24.17209.
^Schroeder JA, Thompson MC, Gardner MM, Gendler SJ (2001). „Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland”. J. Biol. Chem. 276 (16): 13057—64. PMID11278868. doi:10.1074/jbc.M011248200.
^Li Y, Ren J, Yu W, Li Q, Kuwahara H, Yin L, Carraway KL, Kufe D (2001). „The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin”. J. Biol. Chem. 276 (38): 35239—42. PMID11483589. doi:10.1074/jbc.C100359200.
^Tang J, Feng GS, Li W (1997). „Induced direct binding of the adapter protein Nck to the GTPase-activating protein-associated protein p62 by epidermal growth factor”. Oncogene. 15 (15): 1823—32. PMID9362449. doi:10.1038/sj.onc.1201351.
^Chen M, She H, Davis EM, Spicer CM, Kim L, Ren R, Le Beau MM, Li W (1998). „Identification of Nck family genes, chromosomal localization, expression, and signaling specificity”. J. Biol. Chem. 273 (39): 25171—8. PMID9737977. doi:10.1074/jbc.273.39.25171.
^Gauthier ML; Torretto Cheryl; Ly John; Francescutti Valerie; O'Day Danton H (2003). „Protein kinase Calpha negatively regulates cell spreading and motility in MDA-MB-231 human breast cancer cells downstream of epidermal growth factor receptor”. Biochem. Biophys. Res. Commun. 307 (4): 839—46. PMID12878187. doi:10.1016/S0006-291X(03)01273-7.
^Bedrin MS, Abolafia CM, Thompson JF (1997). „Cytoskeletal association of epidermal growth factor receptor and associated signaling proteins is regulated by cell density in IEC-6 intestinal cells”. J. Cell. Physiol. 172 (1): 126—36. PMID9207933. doi:10.1002/(SICI)1097-4652(199707)172:1<126::AID-JCP14>3.0.CO;2-A.
^Sun J; Nanjundan Meera; Pike Linda J; Wiedmer Therese; Sims Peter J (2002). „Plasma membrane phospholipid scramblase 1 is enriched in lipid rafts and interacts with the epidermal growth factor receptor”. Biochemistry. 41 (20): 6338—45. PMID12009895. doi:10.1021/bi025610l.
^Sarmiento M, Puius YA, Vetter SW, Keng YF, Wu L, Zhao Y, Lawrence DS, Almo SC, Zhang ZY (2000). „Structural basis of plasticity in protein tyrosine phosphatase 1B substrate recognition”. Biochemistry. 39 (28): 8171—9. PMID10889023. doi:10.1021/bi000319w.
^Zhang ZY, Walsh AB, Wu L, McNamara DJ, Dobrusin EM, Miller WT (1996). „Determinants of substrate recognition in the protein-tyrosine phosphatase, PTP1”. J. Biol. Chem. 271 (10): 5386—92. PMID8621392. doi:10.1074/jbc.271.10.5386.
^ абTomic S, Greiser U, Lammers R, Kharitonenkov A, Imyanitov E, Ullrich A, Böhmer FD (1995). „Association of SH2 domain protein tyrosine phosphatases with the epidermal growth factor receptor in human tumor cells. Phosphatidic acid activates receptor dephosphorylation by PTP1C”. J. Biol. Chem. 270 (36): 21277—84. PMID7673163. doi:10.1074/jbc.270.36.21277.
^Keilhack H, Tenev T, Nyakatura E, Godovac-Zimmermann J, Nielsen L, Seedorf K, Böhmer FD (1998). „Phosphotyrosine 1173 mediates binding of the protein-tyrosine phosphatase SHP-1 to the epidermal growth factor receptor and attenuation of receptor signaling”. J. Biol. Chem. 273 (38): 24839—46. PMID9733788. doi:10.1074/jbc.273.38.24839.
^{{cite journal| vauthors = Wang SE, Wu FY, Shin I, Qu S, Arteaga CL | title=Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function. | journal=Mol Cell Biol | year= 2005 | volume= 25 | issue= 11 | pages= 4703–15 | pmid=15899872 | doi=10.1128/MCB.25.11.4703-4715.2005 | pmc=1140650 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15899872 }}
^Lu Y, Brush J, Stewart TA (1999). „NSP1 defines a novel family of adaptor proteins linking integrin and tyrosine kinase receptors to the c-Jun N-terminal kinase/stress-activated protein kinase signaling pathway”. J. Biol. Chem. 274 (15): 10047—52. PMID10187783. doi:10.1074/jbc.274.15.10047.
^Keely SJ, Calandrella SO, Barrett KE (2000). „Carbachol-stimulated transactivation of epidermal growth factor receptor and mitogen-activated protein kinase in T(84) cells is mediated by intracellular ca(2+), PYK-2, and p60(src)”. J. Biol. Chem. 275 (17): 12619—25. PMID10777553. doi:10.1074/jbc.275.17.12619.
^Sato K, Kimoto M, Kakumoto M, Horiuchi D, Iwasaki T, Tokmakov AA, Fukami Y (2000). „Adaptor protein Shc undergoes translocation and mediates up-regulation of the tyrosine kinase c-Src in EGF-stimulated A431 cells”. Genes Cells. 5 (9): 749—64. PMID10971656. doi:10.1046/j.1365-2443.2000.00358.x.
^Xia L; Wang Lijuan; Chung Alicia S; Ivanov Stanimir S; Ling Mike Y; Dragoi Ana M; Platt Adam; Gilmer Tona M; Fu Xin-Yuan; Chin Y Eugene (2002). „Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation”. J. Biol. Chem. 277 (34): 30716—23. PMID12070153. doi:10.1074/jbc.M202823200.
^Sehat B; Andersson Sandra; Girnita Leonard; Larsson Olle (2008). „Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis”. Cancer Res. 68 (14): 5669—77. PMID18632619. doi:10.1158/0008-5472.CAN-07-6364.
Filardo EJ (2002). „Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer”. The Journal of Steroid Biochemistry and Molecular Biology. 80 (2): 231—8. PMID11897506. doi:10.1016/S0960-0760(01)00190-X.
Tiganis T (2002). „Protein tyrosine phosphatases: dephosphorylating the epidermal growth factor receptor”. IUBMB Life. 53 (1): 3—14. PMID12018405. doi:10.1080/15216540210811.
Benaim G, Villalobo A (2002). „Phosphorylation of calmodulin. Functional implications”. European Journal of Biochemistry / FEBS. 269 (15): 3619—31. PMID12153558. doi:10.1046/j.1432-1033.2002.03038.x.
Leu TH, Maa MC (2003). „Functional implication of the interaction between EGF receptor and c-Src”. Frontiers in Bioscience. 8 (1-3): s28—38. PMID12456372. doi:10.2741/980.
Anderson NL, Anderson NG (2002). „The human plasma proteome: history, character, and diagnostic prospects”. Molecular & Cellular Proteomics. 1 (11): 845—67. PMID12488461. doi:10.1074/mcp.R200007-MCP200.
Kari C, Chan TO, Rocha de Quadros M, Rodeck U (2003). „Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage”. Cancer Research. 63 (1): 1—5. PMID12517767.
Bonaccorsi L, Muratori M, Carloni V, Zecchi S, Formigli L, Forti G, Baldi E (2003). „Androgen receptor and prostate cancer invasion”. International Journal of Andrology. 26 (1): 21—5. PMID12534934. doi:10.1046/j.1365-2605.2003.00375.x.
Reiter J, Maihle NJ (2003). „Characterization and expression of novel 60-kDa and 110-kDa EGFR isoforms in human placenta”. Annals of the New York Academy of Sciences. 995 (1): 39—47. PMID12814937. doi:10.1111/j.1749-6632.2003.tb03208.x.
Adams TE, McKern NM, Ward CW (2004). „Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor”. Growth Factors. 22 (2): 89—95. PMID15253384. doi:10.1080/08977190410001700998.
Ferguson KM (2004). „Active and inactive conformations of the epidermal growth factor receptor”. Biochemical Society Transactions. 32 (Pt 5): 742—5. PMID15494003. doi:10.1042/BST0320742.
Carlsson J, Ren ZP, Wester K, Sundberg AL, Heldin NE, Hesselager G, Persson M, Gedda L, Tolmachev V, Lundqvist H, Blomquist E, Nistér M (2006). „Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression”. Journal of Neuro-Oncology. 77 (1): 33—45. PMID16200342. doi:10.1007/s11060-005-7410-z.
Scartozzi M, Pierantoni C, Berardi R, Antognoli S, Bearzi I, Cascinu S (2006). „Epidermal growth factor receptor: a promising therapeutic target for colorectal cancer”. Analytical and Quantitative Cytology and Histology / the International Academy of Cytology [And] American Society of Cytology. 28 (2): 61—8. PMID16637508.
Prudkin L, Wistuba II (2006). „Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications”. Annals of Diagnostic Pathology. 10 (5): 306—15. PMID16979526. doi:10.1016/j.anndiagpath.2006.06.011.
Ahmed SM, Salgia R (2006). „Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer”. Respirology. 11 (6): 687—92. PMID17052295. doi:10.1111/j.1440-1843.2006.00887.x.
Cohenuram M, Saif MW (2007). „Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future”. Jop. 8 (1): 4—15. PMID17228128.